Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

BOTOX (Allegran Inc): Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

BOTOX (Allegran Inc) - General Information

Purified botulinum toxin from Clostridium botulinum, purified from culture via dialysis and acid precipitation.

 

Pharmacology of BOTOX (Allegran Inc)

A 150 kDa neurotoxic protein produced from fermentation of Hall strain Clostridium botulinum type A grown in a medium containing casein hydrolysate, glucose and yeast extract. It is purified from the culture solution by dialysis and a series of acid precipitations to a complex consisting of the neurotoxin, and several accessory proteins. BOTOX (Allegran Inc) is not expected to be present in the peripheral blood at measurable levels following IM or intradermal injection at the recommended doses. The recommended quantities of neurotoxin administered at each treatment session are not expected to result in systemic, overt distant clinical effects, i.e. muscle weakness, in patients without other neuromuscular dysfunction. However, sub-clinical systemic effects have been shown by single-fiber electromyography after IM doses of botulinum toxins appropriate to produce clinically observable local muscle weakness.

 

BOTOX (Allegran Inc) for patients

 

BOTOX (Allegran Inc) Interactions

Co-administration of BOTOX® and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.

The effect of administering different botulinum neurotoxin serotypes at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

 

BOTOX (Allegran Inc) Contraindications

BOTOX® is contraindicated in the presence of infection at the proposed injection site(s) and in individuals with known hypersensitivity to any BOTOX® ingredient in the formulation.

 

Additional information about BOTOX (Allegran Inc)

BOTOX (Allegran Inc) Indication

For the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above. Also used cosmetically to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) as well as for the treatment of excessive underarm sweating.

Mechanism Of Action
BOTOX (Allegran Inc) blocks neuromuscular transmission by binding to acceptor sites on motor or sympathetic nerve terminals, entering the nerve terminals, and inhibiting the release of acetylcholine. This inhibition occurs as the neurotoxin cleaves SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within nerve endings.
Generic Name
Botulinum Toxin Type A
Synonyms
BoNT/A; Bontoxilysin A; Botulinum neurotoxin type A precursor; BTX-A
Drug Category
Anti-Wrinkle Agents; Antidystonic Agents; Neuromuscular Blocking Agents
Drug Type
Biotech; Approved; Investigational
Other Brand Names containing Botulinum Toxin Type A
BOTOX (Allegran Inc); Dysport; BOTOX Cosmetic (Allegran Inc);
Absorption
The chemical complexity of Botulinum Toxin Type A combined with its extreme potency limits the opportunity to study its pharmacokinetic profile in humans. Therefore, no human pharmacokinetic studies have been performed. Botulinum Toxin Type A is injected directly into the target organ, a skeletal muscle. Thus, bioavailability of the intravenous or oral route is not of clinical relevance.
Toxicity (Overdose)
Based on toxicological studies, it has been estimated that the human LD50
Dosage Forms of BOTOX (Allegran Inc)
Powder, for solution Intramuscular
Chemical Formula
C6760H10447N1743O2010S32
Botulinum Toxin Type A on Wikipedia
https://en.wikipedia.org/wiki/Botox
Organisms Affected
Humans and other mammals